The endogenous catecholamines, epinephrine and norepinephrine are key regulators of 2 numerous physiologic functions including learning, memory and cardiovascular and endocrine 3 homeostasis. Their dysregulation has been implicated in human conditions like depression, 4 addiction and in cardiovascular and metabolic diseases. Their effects are mediated by three 5 classes of adrenergic receptors (ARs), E, D1 and D2, each comprised of three distinct gene 6 products. They all belong to the superfamily of seven transmembrane G-protein coupled 7 receptors. D1-ARs are critical for a variety of catecholamine actions such as the control of blood 8 pressure, smooth muscle contraction, myocardial function and glycogenolysis. The importance 9 of D1-ARs in physiology and pathophysiology is evidenced by the wide clinical use of D1-AR 10 agonists and antagonists for the treatment of cardiovascular disease, flu and allergy symptoms, 11 and benign prostate hyperplasia (40, 43) . Paradoxically, the molecular mechanisms underlying 12 D1-AR action remain undefined. 13
Historically, the role of D1-ARs in different biologic systems was largely inferred from 14 pharmacologic studies, but the development of transgenic mice with targeted deletion or 15 overexpression of specific D1-AR subtypes has further confirmed the essential role of specific 16 genes and reinduction of a set of fetal genes such as D-skeletal actin, E-myosin heavy chain and 1 PEX1 and HA-AS-PEX1) were generated by using the AdEasy™ XL Adenoviral Vector System 1 (Stratagene) developed by the laboratory of Bert Vogelstein. Briefly, the HA-AS-PEX1 2 adenovirus was generated by first subcloning a 442-bp KpnI/BglII fragment containing proximal 3 part of 5' untranslated region (UTR) and the two first zinc fingers of rat PEX1 gene into 4
KpnI/BglII in Ad5 shuttle vector pAdTrack-CMV (generously provided by Bert Vogelstein) and 5 the adenovirus was generated by recombination with the pAdEasy-1 as described previously 6 (21). The other adenovirus, AS-Pex1 was generated by first subcloning a 366 bp DNA fragment 7 containing of 5'UTR sequence into Bgl II/Hind III of pShuttle-CMV (Stratagene), the shuttle 8 vector is linearized with Pme I and transformed into BJ5183-AD-1 competent cells. 9
Transformants are selected for kanamycin resistance, and recombinants are subsequently 10 identified by restriction digestion. Once a recombinant is identified, it is produced in bulk using 11 the recombination-deficient XL10-Gold® strain. Purified recombinant Ad plasmid DNA is 12 digested with Pac I to expose its inverted terminal repeats (ITRs), and is then used to transfect 13 AD-293 cells where deleted viral assembly genes are complemented in vivo. The virus were 14 produced and titer as previously described (9) or using the BD Adeno-X TM virus purification and 15 titer kits (CLONTECH). Cardiomyocytes were infected by incubation overnight with 10 plaque 16 forming unit (PFU) of HA-AS-PEX1 or 10 to 50 infectious units (ifu) of AS-PEX1 per cell in the 17 culture media. The following day, the media was changed for fresh media. 18
Statistics. The data are reported as mean ± SEM. A Student's unpaired t test was used to 19 compare two groups. Multiple group comparisons were made by using the one-way ANOVA 20 test followed by the Student-Newman-Keuls test. In all cases, differences were considered to be 21 statistically significant when P < 0.05. 22
RESULTS 1
The PERE element contributes to both basal and PE-induced ANF promoter 2 activity. Atrial natriuretic factor (ANF) is the major secretory product of the heart and its 3 promoter has served as a paradigm for the elucidation of the regulatory networks controlling 4 cardiac transcription (46). The ANF promoter contains several regulatory elements required for 5 cell specificity and hormone response. We previously showed that an evolutionary conserved 6 sequence, termed PERE, within the proximal promoter was essential for D1-agonist 7 (phenylephrine, PE) stimulation of ANF promoter activity (1). The effect of a mutation in the 8 PERE sequence that abolishes in vitro interaction with cardiac nuclear proteins was evaluated in 9 primary cardiomyocyte cultures. The introduced mutation (Fig. 1A) was generated in the 10 context of both the full length (-695 bp) and the proximal (-135 bp) ANF promoters. 11
Transfection experiments in ventricular cardiomyocytes showed that, in both contexts, basal 12 promoter activity was reduced by about 40-50%, compared to that of the corresponding wild 13 type constructs (Fig. 1B) . Moreover, the response of the mutant promoters to PE stimulation was 14 reduced by about 50%, confirming the importance of the PERE element for basal as well as PE-15 inducible ANF transcription. 16
Isolation of a novel cardiac cDNA clone encoding a PERE interacting protein. The 17 yeast one-hybrid strategy was used to screen a 1 day old rat cardiomyocyte cDNA library. Three 18 tandem copies of the PERE element were ligated together and subcloned upstream of the 19 minimal promoter of the pHISi-1 and pLacZi reporter plasmids and integrated into the yeast 20 genome of YM4271. For a more stringent library screening, we constructed a dual reporter 21 strain by sequentially integrating the HIS3 and lacZ reporters into the same yeast genome at 22 different loci. Approximately 2.5x10 6 clones were screened in one transformation. Based on 23 large colony size and rapid growth, a total of 130 histidine positive clones were selected. 1
Eighteen of these clones were positive in the E-galactosidase assay and were all sequenced. One 2 cDNA was found to encode a putative transcription factor with multiple zinc finger motifs and 3 was further characterized. In silico sequence searching in the data bases revealed that this cDNA 4 was the rat ortholog of mouse Zfp260, a gene whose function has not been elucidated (accession 5 number: U56862) (6). This cDNA termed PEX1 for PERE complex 1, rescued growth of yeast 6 on his -selective media, but was less potent to drive rapid growth of transformant yeast for the 7 mutant construct. 8
The 4.8 kb PEX1 cDNA contains a 1221 bp open reading frame predicted to encode a 9 407 amino acid protein composed of 13 zinc fingers (ZFs) of the C 2 H 2 -type and H/C links ( Fig.  10 2A and B) which would belong to the Krüppel subfamily of zinc finger proteins (5). In silico 11 sequence analysis did not show any conventional trans-activation domain in the coding region. 12 However, the protein possesses several putative phosphorylation sites for protein kinase C 13 (PKC), protein kinase A and casein kinase II. 14 Comparison of the amino acid sequences of the rat and murine PEX1 showed a high 15 degree of homology (95%). Searching in databases revealed a PEX1-related protein in mouse 16 and human: OZF also named Zfp146 (6,25) whose function is not yet determined. Mouse PEX1 17 is larger than mouse OZF with three additional N-terminal ZFs (ZFs I-III). PEX1 and OZF share 18 high homology in the region containing ZFs IV to XIII (Fig. 2C) . The D. Rerio protein draculin 19 (accession number NP571052.1) and the D. Melanogaster protein CROL (accession number 20 AAF53121.1) are also highly homologous to PEX1 in ZFs IV to XIII region (Fig. 2C ). Draculin 21 is expressed during early patterning of the zebrafish embryo (22) and crooked legs is required for 22 leg morphogenesis and ecdysone-regulated gene expression during Drosophila metamorphosis 1 (13, 14) . 2 PEX1 is an early D1-adrenergic target. We analyzed the expression of the rat PEX1 3 gene by Northern analysis. A single transcript of approximately 4.8 kb was detected in total 4 RNA from embryonic day 14 (e14) heart and from adult heart as well as from cultured 5 cardiomyocytes isolated from 1 or 4 day old rat hearts ( Fig. 3A and B) . PEX1 transcripts were 6 also detected in other tissues, notably in lung, skeletal muscle and adrenal glands (Fig. 3B) . 7
Interestingly, most of these tissues are well known D1-AR targets that express D1-ARs (18). In 8 addition to spatial regulation, PEX1 expression was regulated by D1-adrenergic agonists. PE 9 stimulation of primary cardiomyocyte cultures significantly increased PEX1 mRNA levels as 10 early as 6 h following PE treatment; this induction, which was accompanied by an increase of 11 ANF mRNA ( Fig. 3C and D) , reached 4-fold and was sustained for 48 h (the maximal time 12 examined). 13
In light of these results and since D1-AR-mediated sympathetic hyperactivity is well 14 documented in the spontaneously hypertensive rats (SHR) (41), we analyzed cardiac PEX1 15 mRNA expression in SHR at 6 and 18 weeks of age. As shown in Table 1 , systolic blood 16 pressure (SBP) is increased at both ages in SHR compared to the controls; additionally, older 17 SHR animals develop cardiac hypertrophy. PEX1 mRNA levels were increased 2-fold in both 18 cardiac compartment of 6 and 18 week old SHR (Fig. 4) suggesting that increased PEX1 19 expression correlates with high blood pressure. This was further confirmed by administration of 20 hydralazine, an arterial vasodilator that reduces blood pressure without affecting cardiac 21 hypertrophy. As expected, three weeks of treatment with hydralazine at 25 mg/kg/day led to a 22 significant decrease of SBP but did no affect cardiac hypertrophy (Table 1, 
HW/BW). 23
Hydralazine treatment also blunted the increase in PEX1 mRNA levels in SHR (Fig. 4) . Thus, 1 both in vitro and in vivo PEX1 expression is upregulated by activation of D1-adrenergic 2
receptors. 3
Spatial and temporal regulation of PEX1 in embryonic and postnatal development. 4
To determine the ontogeny, cell type specificity and subcellular localization of PEX1 protein, we 5 generated an anti-PEX1 antibody against residues 1-115 of PEX1, thus avoiding cross-reactivity 6 with the related OZF protein. In Western blots, anti-PEX1 antibody detected ectopically 7 expressed HA-PEX1 in HeLa cells, which was also detected by the anti-HA antibody (Fig. 5A) . 8
The in vitro translated PEX1 but not OZF as well as endogenous PEX1 in cardiomyocyte nuclear 9 extracts were also detected by the anti-PEX antibody ( Fig. 5A and data not shown). 10
Immunocytofluorescence revealed the presence of both transfected and endogenous PEX1 11 exclusively in the nuclei (Fig. 5B) . Consistent with the observed changes at the transcript level 12 (Fig. 3) , protein analysis also revealed that PEX1 level was increased in cardiomyocytes 13 stimulated with PE ( Fig. 5C and D) . 14 Next, we used immunohistochemistry to study the developmental expression of PEX1 in 15 mouse hearts at different embryonic stages, and in postnatal and adult hearts. PEX1 is detected 16 in cardiomyocyte nuclei as early as e9.5 and the heart is the predominant site of PEX1 17 expression at this stage (Fig. 6A ). PEX1 expression is maintained throughout embryonic 18 development in the atria and in the ventricular walls and trabeculae (Fig. 6B ). Labeled cells are 19 also present in the outflow tract, the truncus arteriosus, the developing atrioventricular valve and 20 the cushion mesenchyme (data not shown). PEX1 expression appeared to decrease after e14 and 21 by e17.5, it was spatially redistributed with highest levels in sub-endocardial myocytes and the 22 septum and no expression in epicardial and apical myocytes (Fig. 6B , right panel and data not 23 shown). PEX1 was also strongly expressed in the atrioventricular valve (data not shown). 1 During postnatal development, PEX1 expression decreased in both atria and ventricles (Fig. 6C) . 2
In the adult mouse heart, PEX1 expression was found in the aortic valve and in scattered cells, in 3 atria, ventricles and septum ( Fig. 6C and data not shown) . Interestingly, PEX1 immunoreactivity 4 was markedly upregulated in hypertrophied adult ventricles of transgenic mice overexpressing 5 the angiotensin II receptor (Fig. 6C, right panel) . Thus, PEX1 expression appears to be highly 6 regulated during embryonic and postnatal cardiac development. The pattern of PEX1 protein 7 expression paralleled the findings obtained at the mRNA levels ( Fig. 3 and data not shown). 8
Outside the heart, PEX1 immunoreactivity was found in embryonic and postnatal vascular 9 smooth muscle cells and in epithelial cells of the lung, gut and kidney at sites of epithelial 10 morphogenesis and in the spinal cord ( Fig. 7 and data not shown). 11 PEX1 is a transcriptional regulator and a GATA-4 cofactor. The isolation of PEX1 12 using a one-hybrid strategy reflected the ability of PEX1 to bind to the PERE element. To 13 confirm that endogenous PEX1 is part of the DNA binding complex detected over PERE, we 14 performed electrophoretic mobility shift assay and tested the effect of anti-PEX1 antibody on the 15 binding of cardiac nuclear protein extracts on the PERE probe. As previously described (1), 16 incubation of the PERE probe with cardiomyocyte nuclear extracts lead to the formation of 3 17 specific complexes (Fig. 8A , close arrowheads). Addition of the anti-PEX1 antibody abrogated 18 complex formation, suggesting that PEX1 is part of these complexes and that its presence is 19 required for formation of a DNA-binding complex (Fig. 8A ). The specificity of the PEX 20 antibody was demonstrated by its inability to displace SP1 binding over its probe (Fig. 8A , open 21 arrowheads). We also directly confirmed the ability of PEX1 to bind to the PERE element using 22 gel shifts with bacterially expressed GST-PEX1 protein. Recombinant PEX1 strongly bound to 23 the PERE probe and this binding was competed by excess cold probe and was blocked by the 1 anti-PEX1 antibody (Fig. 8B) . Interestingly, displacement experiments suggested that PEX1 2 binding may be multimeric as faster migrating complexes appeared at lower doses of cold 3 competitor. Consistent with this, recombinant MBP-PEX1 also produced increasingly larger 4 multimeric complexes in a dose-dependent manner (Fig. 8C) . 5
Next, we analyzed the ability of PEX1 to modulate ANF promoter activity. The -695 bp 6 wild type and mutant PERE ANF promoter-luciferase reporter constructs were cotransfected 7 with increasing doses of PEX1 expression vector into different cell types. PEX1 activated the 8 ANF promoter in a dose-dependent manner. This effect was dependent on the presence of the 9 PERE element as its mutation abrogated promoter activation (Fig. 8D ). These results indicate 10 that PEX1 is a transcriptional activator of ANF. 11
To further confirm the role of PEX1 in basal and/or D1-AR-induced transcription, we 12 generated two different adenovirus vectors expressing two antisense PEX1 transcripts (Fig. 9A) , 13 and used them to infect primary cardiomyocyte cultures. As control, cardiomyocytes were 14 infected with an adenovirus expressing LacZ. The effect of the antisense-PEX1 vector on 15 endogenous PEX1 levels was monitored by Western blot and immunohistochemistry. A 2.5-3-16 fold reduction in PEX1 protein was achieved 4 days after infection with 10 PFU/cell (Fig. 9B) . 17
Under these conditions, ANF levels were consistently reduced by 40-50% (Fig. 9C, open  18 circles). The effect of PEX1 depletion on ANF expression was assessed using quantitative PCR 19 (QPCR), immunohistochemistry and by measuring secreted immunoreactive ANF (irANF) in the 20 culture media. Since ANF is constitutively secreted from postnatal ventricular myocytes, 21 measurements of irANF in the media faithfully reflect ANF gene transcription and allow 22 longitudinal assays. As shown in Figure 9C , the two distinct PEX1 antisense vectors produced asignificant, time-dependent decrease in secreted irANF (50-60%). The effect was dose-1 dependent and maximal inhibition was observed after 5 days of adenoviral infection ( Fig. 9C and  2 data not shown), a time course highly similar to the one reported previously for GATA-4 effect 3 using the same approach (9). As expected, cardiomyocytes infected with AS-PEX1 adenovirus 4 had decreased endogenous ANF content and mRNA levels when compared to LacZ infected 5 cardiomyocytes (inset of Fig. 9C and data not shown). Next, we assessed the effect of PEX1 6 knockdown on ANF upregulation in response to PE. As shown in Figure 9D , the presence of the 7 AS-PEX1 adenovirus completely blocked the response to PE stimulation. Interestingly, at lower 8 viral titer, AS-PEX1 blocked PE-induced ANF expression without altering basal levels (data not 9 shown). Thus, the genetic response to D1-adrenergic agonist appeared exquisitely sensitive to 10 intact PEX1 expression. 11
Another feature of D1-AR stimulation of cardiomyocytes is cytoskeletal reorganization 12 (10). PEX1 knockdown also interfered with PE-induced myofibrillar reorganization (Fig. 9E) . 13
These effects on ANF gene expression and on the genetic and cytoskeletal response to PE were 14 highly reminiscent of the ones observed in cardiomyocytes in which GATA-4 levels were 15 downregulated using a similar approach (10,11). We checked whether inhibition of GATA-4 16 might account for the AS-PEX1 phenotype. Using Q-PCR analysis, we were unable to detect 17 any decrease in GATA-4 expression in cardiomyocytes infected with the AS-PEX1 adenovirus; 18 conversely, PEX1 transcripts were not decreased in cardiomyocytes infected with antisense 19 GATA-4 adenovirus (data not shown). Thus, the similar phenotype elicited by downregulation 20 of either GATA-4 or PEX1 was not due to a hierarchical relationship between the two proteins. 21
We then tested the possibility that the similar effects elicited by inhibiting PEX1 or 22
GATA-4 reflect cooperative interaction between the two transcription factors. Using theproximal ANF promoter, we found that PEX1 and GATA-4 functionally cooperate to activate 1 transcription (Fig. 10A) . GATA-4/PEX1 synergy depends on the presence of the GATA binding 2 site but does not require the PERE element, although maximal synergy is achieved when both 3 elements are present. Thus, PEX1/GATA-4 synergy requires GATA-4 binding to DNA while 4 PEX1 may be recruited to the promoter through interaction with GATA-4. Indeed, GATA sites 5 on the (GATA)3x-Luc reporter are sufficient to mediate GATA-4/PEX1 synergy (Fig. 10B) . 6
Consistent with this, GATA-4 and PEX1 were found to physically interact in pull-down assay 7 (Fig. 10C ) likely through direct physical interaction (Fig. 10B) . Structure-function analysis 8
indicates that the C-terminal domain of GATA-4 as well as an intact DNA-binding domain is 9 required for functional cooperation with PEX1. Thus, PEX1 appears to be a novel GATA-4 10 collaborator and an epistatic relationship between the two factors is suggested. Together the data 11 are consistent with an important role for PEX1 in basal and D1-adrenergic-induced cardiac 12 transcription. Moreover, a dual mode for PEX1 action is revealed, one involving direct binding 13 to DNA via PERE elements, and the other involving recruitment to promoter bound GATA-4 via 14 protein-protein interactions. 15
The D1 subfamily of adrenergic receptors mediates several of the biological effects of 18 endogenous catecholamines on the visceral, endocrine, nervous and cardiovascular systems. 19
They also transduce the actions of some psychostimulants and are therefore linked to behavioral 20 processes such as addiction. Despite their evident relevance to physiology and pathophysiology, 21 the mechanisms by which D-AR profoundly alter cell fate and behavior remain undefined. 22 pathways and transcription factors that mediate D1-AR actions remain poorly understood. We 1 now report the isolation of a novel transcription factor enriched in the heart, PEX1/Zfp260, that 2 mediates at least some of the effects of D1-ARs. Our data show that PEX1, a member of the 3
Krüppel family of zinc finger proteins, acts as a transcriptional regulator of the ANF gene and 4 functionally cooperates with GATA-4, a key cardiac regulator. The results also suggest that 5 PEX1/GATA-4 interaction is critical for transducing the nuclear and cytoskeletal effects of D1-6 adrenergic agonists. In addition to identifying a novel regulator of cardiac gene expression, the 7 work reported will help elucidate the signaling cascade linking membrane activation of D1-ARs 8 to nuclear changes in the heart and in other D1-AR target organs. 9 PEX1 shows high similarity to another Krüppel protein, OZF/Zfp146, which is also 10 expressed in the heart and other tissues (25). The two are contiguously present on mouse 11 chromosome 7 and human 19q13 within a region with frequent rearrangements and 12 amplifications in tumors (12). The function of OZF is not known but a role in cellular 13 proliferation could be inferred from the findings that it is overexpressed or amplified in human 14 pancreatic cancer (16) as well as in pancreatic carcinoma cell lines (12). The regulation of PEX1 15 and its role in mediating D1-AR effects on cytoskeletal organization raise the possibility for a 16 role in cell growth. First, PEX1 levels in the heart peak between e9.5-13.5 which is the period of 17 most rapid growth of this organ (37). Postnatally, as cardiomyocyte proliferative ability ceases, 18 PEX1 levels are dramatically downregulated but are upregulated in two models of cardiac 19 hypertrophy. It is noteworthy that this expression pattern is similar to that of ANF, a marker for 20 the hypertrophy genetic program. In cardiomyocyte cultures, PEX1 is required for D1-induced 21 effects of catecholamines. In addition to their well-established functions, catecholamines play 1 important roles in development by acting as morphogens and growth-promoting agents in 2 embryogenesis (39). Indeed, several studies have provided evidence for expression of 3 catecholamine-synthesizing enzymes (15), catecholamines (47,54) and D1-ARs (50) in the heart 4 and other structures during embryonic development. Moreover, targeted disruption of the 5 tyrosine hydroxylase or dopamine E-hydroxylase genes lead to embryonic lethality, apparently of 6 cardiac failure (47,54). In both cases, cardiomyocyte cell size was decreased and they were 7 disorganized resulting in atrophied hearts as early as e10.5 (47). Interestingly, the peak of PEX1 8 expression in the embryonic heart matches the transient burst of phenylethanolamine N-9 methyltransferase (PNMT), the final enzyme in catecholamine synthesis which takes place 10 between e9.5-13.5 (15). Together with its demonstrated function as a transcriptional regulator 11
and an effector of D1-adrenergic signaling in cardiomyocytes, these data raise the intriguing 12 possibility that PEX1 may have a role in the control of cardiomyocyte proliferation and/or the 13 response of cardiac cells to catecholamines during development. In this respect, it is noteworthy 14 that, besides the heart, PEX1 is expressed in catecholamine synthesizing tissues and in D1-AR (10,27). Whether PEX1 acts as a nuclear effector of MAPK or other signaling cascades 10 activated by D1-AR will need to be investigated but the presence of multiple, conserved PKC 11 sites on PEX1 is noteworthy given the documented involvement of PKC in D1-AR signaling. 12
In conclusion, PEX1 and GATA-4 are presently two of only a handful of transcription 13 factors known to be required for nuclear and cytoskeletal response to D1-agonists. Further 14 analysis of PEX1 regulation and mode of action in D1-target organs will provide molecular 15 insight into D1-adrenergic receptor function. Finally, given the co-expression of PEX1 with 16 other members of the GATA family (35), it is tempting to speculate on the role of GATA-PEX1 17 interactions in development and transcriptional regulation by D1-adrenergic receptors. 18
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LacZ were used with the PERE probe; the close arrowheads indicate the position of the DNA 18 binding complexes specifically obtained with the recombinant PEX1 protein.
D) 19
Cardiomyocytes were cotransfected with wild-type and mutant ANF luciferase reporters and 20 increasing amounts of PEX1 expression vector. The data shown represent the mean r SEM of at 21 least six independent determinations. 22 : 
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